News

Suppressor tRNAs as personalized therapy for nonsense mutation-associated pathologies

Read more

Rescue of Full-Length Dystrophin Protein in a Mouse Model of Duchenne Muscular Dystrophy Using an AAV-tRNA Therapeutic

Read more

Tevard Biosciences Names Dr. Elisabeth Gardiner Chief Scientific Officer to Lead Next Phase of tRNA-Based Therapies

Read more

Tevard Reports Data on Suppressor tRNA Therapy Restoring Full-Length Dystrophin in Duchenne Muscular Dystrophy Model

Read more

Tevard to Present Data Demonstrating tRNA-based Therapy Rescued Full-Length Dystrophin and Motor Function in Duchenne Muscular Dystrophy Model

Read more

Tevard Biosciences to Move Corporate Headquarters to Lilly Gateway Labs in Boston’s Seaport

Read more

Industry Veteran and RNA Therapeutics Expert, John Maraganore, Joins Tevard Biosciences as Strategic Advisor and Board Observer

Read more

tRNA therapeutics for genetic diseases

Read more

Tevard Biosciences Appoints Zoya Ignatova to Its Scientific Advisory Board

Read more

Tevard CEO Awarded Henri Termeer Fellowship

Read more